BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Respiratory viruses (RSV, influenza, COVID-19) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for respiratory syncytial virus: 68 (30 sponsors; 23 newly posted in the last 180 days, 7 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 22.8, rank 18 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 17, Phase 2 23, Phase 3 15, Phase 4 1, N/A 11.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pfizer PFE | 15 | NA 8, P3 7 | 6 | 4 |
| GlaxoSmithKline | 6 | P3 3, P2 3 | 2 | 1 |
| Guangzhou Patronus Biotech Co., Ltd. | 4 | P1 2, P3 1, P2 1 | 1 | 0 |
| MAXVAX Biotechnology Limited Liability Company | 4 | P2 1, P3 1, P1 1, NA 1 | 1 | 0 |
| Enanta Pharmaceuticals, Inc ENTA | 2 | P2 1, P3 1 | 1 | 1 |
| Kexing Biopharm Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Shanghai Ark Biopharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Sanofi SNY | 6 | P4 1, P2 2, P1 2, NA 1 | 2 | 1 |
| Shenzhen Shenxin Biotechnology Co., Ltd | 3 | P2 1, P1 2 | 0 | 1 |
| AstraZeneca AZN | 2 | P2 1, NA 1 | 1 | 1 |
| Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. new entrant | 2 | P2 1, P1 1 | 2 | 0 |
| ModernaTX, Inc. | 2 | P1 2 | 1 | 0 |
| Shanghai Institute Of Biological Products | 2 | EARLY_P1 1, P2 1 | 0 | 2 |
| Suzhou Abogen Biosciences Co., Ltd. | 2 | P2 1, P1 1 | 0 | 0 |
| Biothervax SpA new entrant | 1 | P2 1 | 1 | 0 |
| Blue Lake Biotechnology Inc. | 1 | P2 1 | 0 | 0 |
| Clover Biopharmaceuticals AUS Pty CBPHF | 1 | P2 1 | 0 | 0 |
| Clover Biopharmaceuticals USA, LLC CBPHF | 1 | P1 1 | 0 | 0 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. new entrant | 1 | P1 1 | 1 | 1 |
| CSPC Ouyi Pharmaceutical Co., Ltd. new entrant | 1 | P2 1 | 1 | 0 |
| EuBiologics Co.,Ltd | 1 | P1 1 | 0 | 0 |
| Immorna Biotherapeutics, Inc. | 1 | P1 1 | 0 | 0 |
| NextCell Pharma Ab | 1 | P1 1 | 0 | 1 |
| PEACHES BIOTECH | 1 | P2 1 | 0 | 0 |
| Pulmotect, Inc. | 1 | P2 1 | 0 | 1 |
New-entrant sponsors: Shanghai Ark Biopharmaceutical Co., Ltd., Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Biothervax SpA, CSPC Megalith Biopharmaceutical Co.,Ltd., CSPC Ouyi Pharmaceutical Co., Ltd..
Recently stopped trials
- NCT06397768 Sanofi Pasteur, a Sanofi Company - terminated: Sponsor decision Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddler
- NCT06999603 Synairgen Research Ltd. - terminated: Study was stopped due to significantly low patient recruitment rate. Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
- NCT06705140 Sanofi Pasteur, a Sanofi Company - terminated: Sponsor decision A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in
- NCT04919109 Codagenix, Inc - terminated: Sponsor Decision Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
- NCT06585150 Gilead Sciences - terminated: Study was terminated by Sponsor; the decision was not due to any safety findings. Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
- NCT03699202 Shanghai Ark Biopharmaceutical Co., Ltd. - terminated: The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns. Anti-RSV Study in Chinese Patients (ASCENT)
- NCT06784973 Gilead Sciences - terminated: Study was terminated by Sponsor; the decision was not due to any safety findings. Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Azidus Brasil | NCT06817096 Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza | Covid 19; Influenza | not yet recruiting | 340 |
| 2026-12 est. | P2 | Traws Pharma, Inc. TRAW | NCT07371650 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza | Influenza | active not recruiting | 105 |
| 2026-12 est. | P2 | Enanta Pharmaceuticals, Inc ENTA | NCT07482657 A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Vir | RSV Infection; RSV; Respiratory Syncytial Virus (RSV) | recruiting | 150 |
| 2026-12-01 est. | P1/P2 | Sanofi SNY | NCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain | Pandemic Influenza Immunization; Healthy Volunteers | active not recruiting | 720 |
| 2026-12-01 est. | P2/P3 | HealthBio, Inc. | NCT06974084 A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Mara | Long COVID | not yet recruiting | 252 |
| 2026-12-30 est. | P2 | Shionogi | NCT07214571 A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | Respiratory Syncytial Virus Infections | recruiting | 192 |
| 2026-12-31 est. | P2 | GeoVax, Inc. GOVX | NCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myel | active not recruiting | 63 |
| 2027-01-12 est. | P2 | GlaxoSmithKline | NCT07092865 A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following R | Respiratory Syncytial Virus Infections | active not recruiting | 168 |
| 2027-01-18 est. | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Yea | Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization | active not recruiting | 1530 |
| 2027-01-25 est. | P3 | Pfizer PFE | NCT07653100 A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF | Respiratory Syncytial Virus (RSV) | recruiting | 540 |
| 2027-01-28 est. | P3 | ModernaTX, Inc. | NCT07496450 A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Influenza | active not recruiting | 4050 |
| 2027-02-03 est. | P2 | InventVacc Biologicals Inc. | NCT07743008 Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine | Haemophilus Influenzae; Haemophilus Influenzae Type a | active not recruiting | 47 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-10-01 | FDA AdCom | held | AdCom 2026-10-01: Vaccines and Related Biological Products Advisory Committee | ||
| 2026-06-18 | FDA AdCom | held | AdCom 2026-06-18: Vaccines and Related Biological Products Advisory Committee | ||
| 2026-05-28 | FDA AdCom | held | AdCom 2026-05-28: Vaccines and Related Biological Products Advisory Committee | ||
| 2026-03-12 | FDA AdCom | held | AdCom 2026-03-12: Vaccines and Related Biological Products Advisory Committee |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Traws Pharma, Inc. TRAW | NCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Influenza | not yet recruiting | 165 |
| 2026-10-02 est. | P1/P2 | PEACHES BIOTECH | NCT06684379 Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Co | SARS-CoV-2; Influenza, Human; Respiratory Syncytial Virus Infections; Respiratory Distress Syndrome; | recruiting | 50 |
| 2026-10-01 | P1/P2 | AstraZeneca AZN | NCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) | RSV Respiratory Syncytial Virus | active not recruiting | 164 |
| 2026-10 est. | P1/P2 | Aramis Biotechnologies Inc. | NCT07291635 Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine | Influenza | active not recruiting | 728 |
| 2026-10 est. | P2 | ImmunityBio, Inc. IBRX | NCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19. | Long COVID | recruiting | 20 |
| 2026-09-30 est. | P2 | Shanghai Institute Of Biological Products | NCT07327398 Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above | Influenza | not yet recruiting | 1200 |
| 2026-09-30 est. | P3 | GlaxoSmithKline | NCT06534892 An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age | Respiratory Syncytial Virus Infections | active not recruiting | 10212 |
| 2026-09-22 | P3 | BioNTech SE BNTX | NCT07300839 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | COVID-19; SARS-COV-2 Infection | completed | 5240 |
| 2026-09-06 est. | P2 | CastleVax Inc. | NCT07215520 Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults | COVID-19 | active not recruiting | 200 |
| 2026-09 est. | P2 | Vasomune Therapeutics, Inc. | NCT05123755 Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. | Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Res | active not recruiting | 60 |
| 2026-08-26 est. | P2 | ParagonClinicals Inc. | NCT07627815 Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID | Long COVID | recruiting | 82 |
| 2026-08-25 | P3 | Pfizer PFE | NCT07543380 A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. | Respiratory Syncytial Virus (RSV) | completed | 130 |
| 2026-08-24 | P2 | GlaxoSmithKline | NCT07204964 A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above | Influenza, Human | completed | 971 |
| 2026-08-15 | P3 | Invivyd, Inc. IVVD | NCT07655180 Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine | COVID-19 | completed | 210 |
| 2026-08-06 | P2 | BioVie Inc. BIVI | NCT06847191 NE3107 in Adults With Neurological Symptoms of Long COVID | Long COVID | completed | 203 |
| 2026-08-01 est. | P3 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | NCT07113392 A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension | Influenza | not yet recruiting | 144 |
| 2026-08 est. | P3 | Invivyd, Inc. IVVD | NCT07298434 Study of VYD2311 for the Prevention of COVID-19 | COVID-19 | active not recruiting | 1770 |
| 2026-07-31 est. | P3 | MAXVAX Biotechnology Limited Liability Company | NCT07272434 Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) | Respiratory Syncytial Virus (RSV) | recruiting | 25000 |
| 2026-07-30 est. | P3 | Pfizer PFE | NCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Ho | COVID-19 | recruiting | 160 |
| 2026-07-24 | P3 | BioNTech SE BNTX | NCT07222384 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe C | COVID-19; SARS-COV-2 Infection | completed | 344 |
| 2026-07-24 | P3 | ModernaTX, Inc. | NCT06067230 A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | Respiratory Syncytial Virus | completed | 1153 |
| 2026-07-20 | P3 | GlaxoSmithKline | NCT07220109 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Resp | Respiratory Syncytial Virus Infections | active not recruiting | 750 |
| 2026-07-10 | P3 | BioNTech SE BNTX | NCT05543616 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children | SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19 | completed | 4338 |
| 2026-06-26 | P3 | Sinovac Biotech Co., Ltd SVA | NCT07211152 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women | Influenza | completed | 150 |
| 2026-06-15 | P2 | CyanVac LLC | NCT06742281 A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults | COVID-19 | completed | 432 |
| 2026-06-01 est. | P1/P2 | Gylden Pharma Ltd | NCT05633446 Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19) | Coronavirus; SARS-CoV-2 Infection; COVID-19 | not yet recruiting | 110 |
| 2026-05-26 | P3 | Seqirus | NCT06087640 A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults | Influenza, Human | completed | 38769 |
| 2026-05-25 | P2 | ModernaTX, Inc. | NCT06143046 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers | Respiratory Syncytial Virus | completed | 360 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "respiratory syncytial virus"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.